Ecdysterone and Oxandrolone Interaction: Avoid | Peptide Database

Used as a diagnostic agent in Japan for assessing growth hormone deficiency in clinical settings. Stimulates endogenous growth hormone release through ghrelin receptor activation. Indirectly increases IGF-1 levels through enhanced GH secretion. Enhanced muscle protein synthesis through elevated growth hormone and IGF-1 levels. Improved lipolysis and body composition through GH-mediated fat oxidation. Faster recovery from exercise and improved sleep quality. Myoprotective effects in muscle atrophy models through GHS-R1a stimulation. Cytoprotective effects observed in cardiac tissue research.

Phenylpiracetam enhances memory consolidation and retrieval through AMPA receptor modulation and increased dopaminergic signaling. Clinical studies in patients with cognitive impairment from organic brain disease and cerebrovascular conditions have shown statistically significant improvements in memory test scores. The dopaminergic and noradrenergic activity of phenylpiracetam provides a clean stimulant effect that enhances sustained attention, task motivation, and mental stamina. This distinguishes it from piracetam and most other racetams, which lack meaningful stimulant properties. Phenylpiracetam improves physical endurance, reduces perception of effort, and enhances exercise tolerance. These effects were significant enough to earn it a place on the WADA prohibited substances list. Athletes have reported improved stamina and recovery during competition. Phenylpiracetam was approved in Russia for asthenia and chronic fatigue states of various origins. Clinical trials demonstrated improvements in subjective energy, motivation, and capacity for sustained mental and physical work in patients with post-infectious, cerebrovascular, and post-traumatic asthenia. Approved for cognitive deficits associated with cerebrovascular disease. Patients showed improvements in memory, attention, and overall cognitive functioning, along with reductions in depression and anxiety. Phenylpiracetam has demonstrated anticonvulsant properties in preclinical models and was included in the Russian clinical indication for adjunctive treatment of convulsive conditions. Developed for Soviet cosmonauts to withstand extreme cold. Animal studies confirm that phenylpiracetam significantly increases resistance to hypothermia. This property is unique among the racetam family and has potential applications for military, aerospace, and extreme sports contexts. The dopaminergic activity of phenylpiracetam provides mood-elevating effects that may benefit individuals with depression, particularly anhedonic subtypes. This remains investigational, with supporting evidence primarily from clinical observations and the known pharmacological profile rather than large-scale controlled trials.